X0206 3 2019-04-03 0 0001426332 NGM BIOPHARMACEUTICALS INC NGM 0001347769 COLUMN GROUP L P 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001600420 COLUMN GROUP II, LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 0 0001614627 COLUMN GROUP GP, LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 1 General Partner 0001645340 Column Group Management LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 0 0 1 0 0001645333 Column Group II GP, LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 0 1 1 General Partner Common Stock 475957 D Series A Preferred Stock Common Stock 6000000 D Series B Preferred Stock Common Stock 4204467 D Series C Preferred Stock Common Stock 1188667 D Series D Preferred Stock Common Stock 1700000 D The number of shares of Common Stock reflects a 1-for-2 reverse stock split which became effective March 22,2019. Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock is convertible into the Issuer's Common Stock on a 1-for-2 basis and has no expireation date. The number of underlying shares of Common Stock reported in Column 3 of Table II reflects the 1-for-2 reverse stock split pursuant to which every 2 shares of Preferred Stock will convert into one share of Common Stock of the Issuer, effective upon the closig of the Issuer's initial public offering, for no additional consideration. Consists of 275,957 shares of Common Stock held directly by The Column Group II, LP ("TCG II LP"), 100,000 shares of Common Stock held directly by The Column Group GP, LP ("TCG GP") and 100,000 shares of Common Stock held directly by The Column Group Management, LP ("TCGM LP"). The reporting persons disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. The securities are directly held by TCG GP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. The securities are directly held by TCGM LP. The managing partners of TCGM LP are David Goeddel and Peter Svennilson. The managing partners of TCGM LP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by TCG GP, the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Consists of 3,600,000 shares of Series B Preferred Stock held directly by TCG LP and 604,467 shares of Series B Preferred Stock held directly by TCG II LP. Consists of 1,170,000 shares of Series C Preferred Stock held directly by TCG LP and 18,667 shares of Series C Preferred Stock held directly by TCG II LP. Consists of 333,333 shares of Series D Preferred Stock held directly by TCG LP and 1,366,667 shares of Series D Preferred Stock held directly by TCG II LP. /s/ Jennifer J. Carlson, Attorney-in-Fact 2019-04-03